Drug delivery systems such as the travoprost intracameral implant are being developed to address poor patient adherence with topical glaucoma medications.

Both the slow-eluting and fast-eluting travoprost intracameral implant provided clinically relevant intraocular pressure (IOP) reductions through 12 months in patients with open-angle glaucoma and ocular hypertension.

The IOP reductions with the slow-eluting travoprost intracameral implant were non-inferior to those produced by twice-daily instillations of timolol ophthalmic solution, 0.5% through 12 months; the IOP reductions with the fast-eluting implant were non-inferior to timolol through 9 months.

Topical glaucoma medication burden was substantially reduced in patients who had received travoprost intracameral implant 12 months following implant administration.

The intracameral implants had an acceptable safety profile.